generations of glp 1 agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1R Agonists for Weight Loss

A detailed summary of findings table was constructed to present the quality of evidence across the included outcomes and studies (Supplementary Appendix C)

2021;5(7) doi: 10.1093/cdn/nzab093

The meta-analysis identified a nonsignificant increase of 2.4 bpm (95% CI 0.24, 5.05) with GLP-1RA treatment relative to placebo

There was also an association with pre-operative gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, bloating) and the degree of residual gastric contents

If in fact future studies robustly establish a beneficial effect of the drug class in HF, it may allow for broader adoption of GLP-1 RAs in the prevalent CVD, ultimately contributing to addressing the unmet medical need that continues to persist in the prevention or management of, in particular, HFpEF

HEOR = Health Economics and Outcomes Research